Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy

Area of Science:

• Nanomedicine
• Biotechnology
• Oncology

Background:

• Theranostics combines diagnostic and therapeutic functions for synergistic or sequential treatment.
• Lipid-based nanocarriers are investigated for their biocompatibility, biodegradability, and targeting abilities in theranostics.
• Precision medicine aims to tailor treatments using real-time diagnostic information.

Purpose of the Study:

• To review recent advances in lipid-based nanocarriers for cancer theranostics.
• To explore strategies for enhancing in vivo performance of these nanocarriers.
• To identify and discuss challenges and barriers to clinical translation.

Main Methods:

• Literature review of current research on lipid-based nanocarriers in cancer theranostics.
• Analysis of strategies for improving in vivo performance.
• Examination of challenges such as regulatory hurdles, cost, and technological integration.

Main Results:

• Lipid-based nanocarriers show significant potential for improving cancer theranostics and precision medicine.
• Various approaches exist to enhance their in vivo performance and therapeutic efficacy.
• Key challenges include regulatory issues, high costs, and the need for technological integration.

Conclusions:

• Lipid-based nanocarriers hold promise for personalized medicine, reducing side effects and improving patient outcomes.
• Multidisciplinary collaboration is essential to overcome barriers and facilitate clinical translation.
• Addressing these challenges will unlock the full potential of nanomedicine in theranostics.